March 3, 2014 Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom. Dendreon will make PROVENGE commercially available to patients within the approved label through Centers of Excellence using its Contract Manufacturing Organization, PharmaCell. Centers of Excellence are institutions where a high volume of prostate cancer …
Cancer Vaccine Clinical Challenges
Therapeutic cancer vaccines have been penned as the future of cancer treatment. But thus far we have seen a number of high profile late stage failures of cancer vaccines. So what is causing these late stage drop-outs? Below we list just a few of the common reasons cited for the poor performance we have witnessed of many therapeutic cancer vaccines …